Cargando…

Targeting genetic alterations in protein methyltransferases for personalized cancer therapeutics

The human protein methyltransferases (PMTs) constitute a large enzyme class composed of two families, the protein lysine methyltransferases (PKMTs) and the protein arginine methyltransferases (PRMTs). Examples have been reported of both PKMTs and PRMTs that are genetically altered in specific human...

Descripción completa

Detalles Bibliográficos
Autores principales: Copeland, R A, Moyer, M P, Richon, V M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3579158/
https://www.ncbi.nlm.nih.gov/pubmed/23160372
http://dx.doi.org/10.1038/onc.2012.552
_version_ 1782260101111873536
author Copeland, R A
Moyer, M P
Richon, V M
author_facet Copeland, R A
Moyer, M P
Richon, V M
author_sort Copeland, R A
collection PubMed
description The human protein methyltransferases (PMTs) constitute a large enzyme class composed of two families, the protein lysine methyltransferases (PKMTs) and the protein arginine methyltransferases (PRMTs). Examples have been reported of both PKMTs and PRMTs that are genetically altered in specific human cancers, and in several cases these alterations have been demonstrated to confer a unique dependence of the cancer cells on PMT enzymatic activity for the tumorigenic phenotype. Examples of such driver alterations in PMTs will be presented together with a review of current efforts towards the discovery and development of small-molecule inhibitors of these enzymes as personalized cancer therapeutics.
format Online
Article
Text
id pubmed-3579158
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-35791582013-02-22 Targeting genetic alterations in protein methyltransferases for personalized cancer therapeutics Copeland, R A Moyer, M P Richon, V M Oncogene Review The human protein methyltransferases (PMTs) constitute a large enzyme class composed of two families, the protein lysine methyltransferases (PKMTs) and the protein arginine methyltransferases (PRMTs). Examples have been reported of both PKMTs and PRMTs that are genetically altered in specific human cancers, and in several cases these alterations have been demonstrated to confer a unique dependence of the cancer cells on PMT enzymatic activity for the tumorigenic phenotype. Examples of such driver alterations in PMTs will be presented together with a review of current efforts towards the discovery and development of small-molecule inhibitors of these enzymes as personalized cancer therapeutics. Nature Publishing Group 2013-02-21 2012-11-19 /pmc/articles/PMC3579158/ /pubmed/23160372 http://dx.doi.org/10.1038/onc.2012.552 Text en Copyright © 2013 Macmillan Publishers Limited http://creativecommons.org/licenses/by-nc-nd/3.0/ This work is licensed under the Creative Commons Attribution-NonCommercial-No Derivative Works 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/
spellingShingle Review
Copeland, R A
Moyer, M P
Richon, V M
Targeting genetic alterations in protein methyltransferases for personalized cancer therapeutics
title Targeting genetic alterations in protein methyltransferases for personalized cancer therapeutics
title_full Targeting genetic alterations in protein methyltransferases for personalized cancer therapeutics
title_fullStr Targeting genetic alterations in protein methyltransferases for personalized cancer therapeutics
title_full_unstemmed Targeting genetic alterations in protein methyltransferases for personalized cancer therapeutics
title_short Targeting genetic alterations in protein methyltransferases for personalized cancer therapeutics
title_sort targeting genetic alterations in protein methyltransferases for personalized cancer therapeutics
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3579158/
https://www.ncbi.nlm.nih.gov/pubmed/23160372
http://dx.doi.org/10.1038/onc.2012.552
work_keys_str_mv AT copelandra targetinggeneticalterationsinproteinmethyltransferasesforpersonalizedcancertherapeutics
AT moyermp targetinggeneticalterationsinproteinmethyltransferasesforpersonalizedcancertherapeutics
AT richonvm targetinggeneticalterationsinproteinmethyltransferasesforpersonalizedcancertherapeutics